RxDoctor Payments Data

Jennifer Dasque

Family · Winter Park, FLNPI 1881183168

Payments from drug & device makers

$2,356in general payments, 2019–2025

Across 123 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$408
  • AstraZeneca$357
  • Novo Nordisk$264
  • GSK$257
  • Amarin Pharma, Inc.$149
  • Abbott$142
  • plus $778 from 22 others

What the payments were for

  • Food & beverage$2,34299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,356 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$60,596
Medicare patients
225
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide16$15,706
JardianceEmpagliflozin15$11,949
MounjaroTirzepatide11$11,640
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,615
EliquisApixaban14$10,530
SynthroidLevothyroxine Sodium40$2,126
Albuterol Sulfate HfaAlbuterol Sulfate31$1,188
Rosuvastatin Calcium79$903
Levothyroxine Sodium51$387
Metoprolol Succinate26$346
Escitalopram Oxalate29$339
Amlodipine Besylate63$335
Lisinopril32$282
Losartan Potassium26$270
Gabapentin15$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$72$27,34627 claims
Boehringer IngelheimJardiance$95$11,94915 claims
GSKTrelegy Ellipta$257$11,61518 claims
AbbVieSynthroid$408$2,12640 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$38751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →